The AstraZeneca COVID vaccine is now available to Australians over 50. Here's what you need to know before you roll up your sleeve.
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
The R21 vaccine protected three-quarters of children against malaria in trials.
Britain moves to protect itself from the B1617 variant, which vaccines may be less effective against.
Current assessments of the risk of blood clots are still uncertain.
Side effects generally indicate a natural immune response and will resolve in a few days.
Both the AstraZeneca and Johnson & Johnson vaccines are now being investigated for links to rare blood disorders.
European regulators are investigating a possible link between the vaccine and a second rare blood disorder.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
The mechanisms behind vaccine-related and pill-related clots are quite different.
How do we reasonably and accurately balance the risks of the AstraZeneca vaccine against the benefits? Conceptualising risk can be tricky, but the government's latest advice is sensible.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
The UK's proposal to give under-30s other vaccines shouldn't be too disruptive, but in Europe, greater restrictions look likely.
All vaccines and medications come with risks. But the risks of delaying vaccination are far higher.
Scientists have called it "vaccine-induced prothrombotic immune thrombocytopenia", or VIPIT. The condition is characterised by a shortage of platelets in the blood.
We need to stop relying on small GP clinics and urgently move towards using mass vaccination hubs like stadiums, schools and parks.
Exports of the vaccine continue to be a point of contention between the EU and UK, while newly released US trial results are quickly amended.
These results can help allay previous concerns in Europe about a lack of trial data for older people.
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.